Imaging of Cannabinoid 1 Receptors Using [11C]OMAR and PET

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01719497
Recruitment Status : Active, not recruiting
First Posted : November 1, 2012
Last Update Posted : April 25, 2017
Information provided by (Responsible Party):
Marc Potenza, Yale University

Brief Summary:
The aim of the present study is to conduct a human trial of [C-11]OMAR, a new PET imaging agent for the brain cannabinoid type 1 receptors (CB1), to determine its pharmacokinetics and binding characteristics.

Condition or disease Intervention/treatment
Obesity Alcohol Dependence High Stress Drug: [C-11]OMAR

Detailed Description:
This is a pilot, 2-part study to assess the kinetics of radioactivity in medically healthy subjects, subjects with alcohol dependency (AD), and obese subjects following the intravenous administration of the imaging agent [C-11]OMAR.

Study Type : Observational
Estimated Enrollment : 120 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Imaging of Cannabinoid 1 Receptors Using [11C]OMAR and PET
Study Start Date : June 2009
Actual Primary Completion Date : June 2015
Estimated Study Completion Date : June 2018

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
Subjects diagnosed with alcohol dependence
Drug: [C-11]OMAR
PET radioligand

Subjects diagnosed with obesity
Drug: [C-11]OMAR
PET radioligand

High Stress
Subjects diagnosed with high stress
Drug: [C-11]OMAR
PET radioligand

Subjects deemed medically healthy
Drug: [C-11]OMAR
PET radioligand

Primary Outcome Measures :
  1. No outcome measures for this study, this is an imaging study only [ Time Frame: Upon study completion ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
N = 30 Medically Healthy control subjects N = 30 Subjects with high stress exposure N = 30 Subjects with Alcohol Dependence (AD) N = 30 Obese subjects

Inclusion Criteria:

  1. Are overtly healthy males or females (other than AD or obesity), as determined by medical history and physical examination. Males and females with stable medical problems that, in the investigator's opinion, will not significantly alter the disposition of the drug, will not place the subject at increased risk by participating in the study, and will not interfere with interpretation of the data.
  2. Are between the ages of 18 and 65 years, inclusive.
  3. Have clinical laboratory test results within normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not clinically significant by the investigator. (Note: specific laboratory tests are listed in section 3.4)
  4. Have arterial access sufficient to allow blood sampling as per the protocol.
  5. Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures.
  6. Have given written informed consent approved by the ethical review board governing the site.

Exclusion Criteria:

  1. Are currently enrolled in, or discontinued within the last [30 days] from, a clinical trial involving an off-label use of an investigational drug or device, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
  2. Current substance abuse (other than AD) including marijuana use, or severe systemic disease based on history and physical exam.
  3. Laboratory tests with clinically significant abnormalities or positive urine toxicology screen. (Note: specific laboratory tests are listed in section 3.4)
  4. Prior participation in other research protocols in the last year such that radiation exposure would exceed the annual limits.
  5. Presence of ferromagnetic metal in the body or heart pacemaker.
  6. Are persons who have previously completed or withdrawn from this study or any other study investigating [C-11]OMAR.
  7. Regularly use known drugs of abuse (other than alcohol) within 30 days of the study and/or show positive findings on urinary drug screening.
  8. Show evidence of human immunodeficiency virus (HIV) and/or positive human HIV antibodies.
  9. Are women with a positive pregnancy test or women who are lactating.
  10. Have a history of head trauma with prolonged loss of consciousness (>10 minutes), or any neurological condition including stroke or seizure (excluding a single childhood febrile seizure) or a history of migraine headaches
  11. History of adverse drug reactions or intolerance to more than three types of systemically administered medications
  12. Have used any prescription medication (except for oral contraceptives or hormone replacement therapy) or over-the-counter medication (including herbal remedies or diet aids) within 14 days of the imaging session. Multiple vitamins are specifically permitted
  13. Have implanted or embedded metal objects or fragments in the head or body that would present a risk during the MRI scanning procedure, or have worked with ferrous metals either as a vocation or hobby (for example, as a sheet metal worker, welder, or machinist) in such a way that might have led to unknown, indwelling metal fragments that could cause injury if they moved in response to placement in the magnetic field
  14. Have had exposure to ionizing radiation that in combination with the study tracer would result in a cumulative exposure that exceeds recommended exposure limits

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01719497

United States, Connecticut
Yale University School of Medicine
New Haven, Connecticut, United States, 06510
Sponsors and Collaborators
Yale University
Principal Investigator: Marc N Potenza, MD, PhD Yale University

Responsible Party: Marc Potenza, Professor of Psychiatry, Child Study, and Neurobiology, Yale University Identifier: NCT01719497     History of Changes
Other Study ID Numbers: 0906005296
First Posted: November 1, 2012    Key Record Dates
Last Update Posted: April 25, 2017
Last Verified: April 2017

Additional relevant MeSH terms:
Alcohol-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders